Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 103

1.

The role of salvage lymph node dissection in nonmetastatic castration-resistant prostate cancer: A single center experience.

Boeri L, Sharma V, Nehra A, Kwon E, Karnes RJ.

Urol Oncol. 2020 Feb;38(2):38.e9-38.e16. doi: 10.1016/j.urolonc.2019.09.016. Epub 2019 Oct 23.

PMID:
31653561
2.

Mid-term Outcomes Following Salvage Lymph Node Dissection for Prostate Cancer Nodal Recurrence Status Post-radical Prostatectomy.

Zattoni F, Nehra A, Murphy CR, Rangel L, Mynderse L, Lowe V, Kwon E, Karnes RJ.

Eur Urol Focus. 2016 Dec;2(5):522-531. doi: 10.1016/j.euf.2016.01.008. Epub 2016 Feb 10.

PMID:
28723518
3.

The role of salvage extended lymph node dissection in patients with rising PSA and PET/CT scan detected nodal recurrence of prostate cancer.

Porres D, Pfister D, Thissen A, Kuru TH, Zugor V, Buettner R, Knuechel R, Verburg FA, Heidenreich A.

Prostate Cancer Prostatic Dis. 2017 Mar;20(1):85-92. doi: 10.1038/pcan.2016.54. Epub 2016 Nov 8.

PMID:
27824042
4.

EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer.

Heidenreich A, Bastian PJ, Bellmunt J, Bolla M, Joniau S, van der Kwast T, Mason M, Matveev V, Wiegel T, Zattoni F, Mottet N; European Association of Urology.

Eur Urol. 2014 Feb;65(2):467-79. doi: 10.1016/j.eururo.2013.11.002. Epub 2013 Nov 12. Review.

PMID:
24321502
5.

Robotic salvage lymph node dissection for nodal-only recurrences after radical prostatectomy: Perioperative and early oncological outcomes.

Linxweiler J, Saar M, Al-Kailani Z, Janssen M, Ezziddin S, Stöckle M, Siemer S, Ohlmann CH.

Surg Oncol. 2018 Jun;27(2):138-145. doi: 10.1016/j.suronc.2018.02.010. Epub 2018 Feb 24.

PMID:
29937163
6.

Comparison of Peri-operative and Early Oncological Outcomes of Robot-Assisted vs. Open Salvage Lymph Node Dissection in Recurrent Prostate Cancer.

Devos G, Muilwijk T, Raskin Y, Calderon V, Moris L, Van den Broeck T, Berghen C, De Meerleer G, Albersen M, Van Poppel H, Everaerts W, Joniau S.

Front Oncol. 2019 Sep 4;9:781. doi: 10.3389/fonc.2019.00781. eCollection 2019.

7.

Sentinel Lymph Node Dissection to Select Clinically Node-negative Prostate Cancer Patients for Pelvic Radiation Therapy: Effect on Biochemical Recurrence and Systemic Progression.

Grivas N, Wit E, Pos F, de Jong J, Vegt E, Bex A, Hendricksen K, Horenblas S, KleinJan G, van Rhijn B, van der Poel H.

Int J Radiat Oncol Biol Phys. 2017 Feb 1;97(2):347-354. doi: 10.1016/j.ijrobp.2016.10.016. Epub 2016 Oct 19.

PMID:
28068243
8.

Identifying the Optimal Candidate for Salvage Lymph Node Dissection for Nodal Recurrence of Prostate Cancer: Results from a Large, Multi-institutional Analysis.

Fossati N, Suardi N, Gandaglia G, Bravi CA, Soligo M, Karnes RJ, Shariat S, Battaglia A, Everaerts W, Joniau S, Van Poppel H, Rajarubendra N, Gill IS, Larcher A, Mottrie A, Schmautz M, Heidenreich A, Kalz A, Osmonov D, Juenemann KP, Herlemann A, Gratzke C, Stief C, Montorsi F, Briganti A.

Eur Urol. 2019 Jan;75(1):176-183. doi: 10.1016/j.eururo.2018.09.009. Epub 2018 Oct 6.

PMID:
30301694
9.

Salvage lymph node dissection after 68Ga-PSMA or 18F-FEC PET/CT for nodal recurrence in prostate cancer patients.

Herlemann A, Kretschmer A, Buchner A, Karl A, Tritschler S, El-Malazi L, Fendler WP, Wenter V, Ilhan H, Bartenstein P, Stief CG, Gratzke C.

Oncotarget. 2017 Sep 21;8(48):84180-84192. doi: 10.18632/oncotarget.21118. eCollection 2017 Oct 13.

10.

Can pelvic node dissection at radical prostatectomy influence the nodal recurrence at salvage lymphadenectomy for prostate cancer?

Sivaraman A, Benfante N, Touijer K, Coleman J, Scardino P, Laudone V, Eastham J.

Investig Clin Urol. 2018 Mar;59(2):83-90. doi: 10.4111/icu.2018.59.2.83. Epub 2018 Feb 22.

11.

Contemporary role of salvage lymphadenectomy in patients with recurrence following radical prostatectomy.

Abdollah F, Briganti A, Montorsi F, Stenzl A, Stief C, Tombal B, Van Poppel H, Touijer K.

Eur Urol. 2015 May;67(5):839-49. doi: 10.1016/j.eururo.2014.03.019. Epub 2014 Mar 26. Review.

PMID:
24698524
12.

Long-term outcomes of salvage lymph node dissection for clinically recurrent prostate cancer: results of a single-institution series with a minimum follow-up of 5 years.

Suardi N, Gandaglia G, Gallina A, Di Trapani E, Scattoni V, Vizziello D, Cucchiara V, Bertini R, Colombo R, Picchio M, Giovacchini G, Montorsi F, Briganti A.

Eur Urol. 2015 Feb;67(2):299-309. doi: 10.1016/j.eururo.2014.02.011. Epub 2014 Feb 18.

PMID:
24571959
13.

Long-term PSA-free survival and castration-free survival with delayed antiandrogen therapy in patients with one versus two or more positive nodes at prostatectomy.

Lodde M, Lacombe L, Naselli A, Puppo P, Mian M, Fradet Y.

World J Urol. 2013 Apr;31(2):293-7. doi: 10.1007/s00345-012-0827-z. Epub 2012 Jan 24.

PMID:
22270262
14.

Prospective evaluation of the performance of [68Ga]Ga-PSMA-11 PET/CT(MRI) for lymph node staging in patients undergoing superextended salvage lymph node dissection after radical prostatectomy.

Abufaraj M, Grubmüller B, Zeitlinger M, Kramer G, Seitz C, Haitel A, Baltzer P, Hacker M, Wadsak W, Pfaff S, Wiatr T, Mitterhauser M, Shariat SF, Hartenbach M.

Eur J Nucl Med Mol Imaging. 2019 Sep;46(10):2169-2177. doi: 10.1007/s00259-019-04361-0. Epub 2019 Jun 29.

15.

Ultra-early versus early salvage androgen deprivation therapy for post-prostatectomy biochemical recurrence in pT2-4N0M0 prostate cancer.

Taguchi S, Fukuhara H, Azuma T, Suzuki M, Fujimura T, Nakagawa T, Ishikawa A, Kume H, Igawa Y, Homma Y.

BMC Urol. 2014 Oct 16;14:81. doi: 10.1186/1471-2490-14-81.

16.

Does race predict the development of metastases in men who receive androgen-deprivation therapy for a biochemical recurrence after radical prostatectomy?

Vidal AC, Howard LE, De Hoedt A, Kane CJ, Terris MK, Aronson WJ, Cooperberg MR, Amling CL, Lechpammer S, Flanders SC, Freedland SJ.

Cancer. 2019 Feb 1;125(3):434-441. doi: 10.1002/cncr.31808. Epub 2018 Nov 14.

PMID:
30427535
17.

The Role of Prostate-specific Antigen Persistence After Radical Prostatectomy for the Prediction of Clinical Progression and Cancer-specific Mortality in Node-positive Prostate Cancer Patients.

Bianchi L, Nini A, Bianchi M, Gandaglia G, Fossati N, Suardi N, Moschini M, Dell'Oglio P, Schiavina R, Montorsi F, Briganti A.

Eur Urol. 2016 Jun;69(6):1142-8. doi: 10.1016/j.eururo.2015.12.010. Epub 2015 Dec 31.

PMID:
26749093
18.

Salvage pelvic lymph node dissection in recurrent prostate cancer: surgical and early oncological outcome.

Claeys T, Van Praet C, Lumen N, Ost P, Fonteyne V, De Meerleer G, Lambert B, Delrue L, De Visschere P, Villeirs G, Decaestecker K.

Biomed Res Int. 2015;2015:198543. doi: 10.1155/2015/198543. Epub 2015 Jan 28.

19.

Extended vs standard lymph node dissection in robot-assisted radical prostatectomy for intermediate- or high-risk prostate cancer: a propensity-score-matching analysis.

Kim KH, Lim SK, Kim HY, Shin TY, Lee JY, Choi YD, Chung BH, Hong SJ, Rha KH.

BJU Int. 2013 Jul;112(2):216-23. doi: 10.1111/j.1464-410X.2012.11765.x. Epub 2013 Jan 29.

20.

Anticancer Activity and Tolerance of Treatments Received Beyond Progression in Men Treated Upfront with Androgen Deprivation Therapy With or Without Docetaxel for Metastatic Castration-naïve Prostate Cancer in the GETUG-AFU 15 Phase 3 Trial.

Lavaud P, Gravis G, Foulon S, Joly F, Oudard S, Priou F, Latorzeff I, Mourey L, Soulié M, Delva R, Krakowski I, Laguerre B, Théodore C, Ferrero JM, Beuzeboc P, Habibian M, Rolland F, Deplanque G, Pouessel D, Zanetta S, Berdah JF, Dauba J, Baciuchka M, Platini C, Linassier C, Tubiana-Mathieu N, Machiels JP, Kouri CE, Ravaud A, Suc E, Eymard JC, Hasbini A, Bousquet G, Culine S, Boher JM, Tergemina-Clain G, Legoupil C, Fizazi K.

Eur Urol. 2018 May;73(5):696-703. doi: 10.1016/j.eururo.2017.09.022. Epub 2017 Oct 23.

PMID:
29074061

Supplemental Content

Support Center